Federal investigation sought to determine source of prescription pain medication shortages

Federal investigation sought to determine source of prescription pain medication shortages
Federal investigation sought to determine source of prescription pain medication shortages

Top U.S. lawmakers are concerned that overregulation of prescription pain medications is causing an inadvertent shortage of the controlled — and often necessary — controlled substances.

Sens. Charles Grassley (R-IA) and Sheldon Whitehouse (D-RI) asked the Government Accountability Office to find out if a federal Drug Enforcement Agency limit on the production of controlled substances is causing a shortage. Current DEA laws set limits for drug makers on the volume of controlled substances they produce. These drugs include prescription painkillers and tranquilizers, drugs that are commonly used to treat nursing home residents.

The senators, both of whom sit on the Senate Judiciary Committee, said that prescription painkillers and tranquilizers appear often on the Food and Drug Administration's drug shortage list.

“The Drug Enforcement Administration has to walk a fine line between managing dangerous controlled substances like painkillers and making sure there are adequate supplies for legitimate medicine,” Grassley, the ranking committee member, wrote in his letter to the GAO.

Lawmakers such as Sen. Herb Kohl (D-WI) have been outspoken in advocating for nursing home residents who need access to these medications for pain management.

Click here to read the full letter.

More in News

Government agency launches health IT webpage for long-term care providers

Government agency launches health IT webpage for long-term ...

The Office of the National Coordinator for Health Information Technology has unveiled a new webpage with information and resources for long-term and post-acute (LTPAC) providers.

FDA responds to provider pressure, backs off stricter control of fecal transplants ...

Individuals with treatment-resistant Clostridium difficile can undergo fecal transplants after giving informed consent, the Food and Drug Administration recently announced. This is a victory for providers, who pushed back after the FDA recently announced it would tighten regulations around the transplants.

Judge denies Omnicare's 'untimely' motion to disqualify whistleblower in nursing home kickbacks ...

Omnicare has failed to disqualify a whistleblower who alleges the long-term care pharmacy paid kickbacks to nursing homes, ruled a district court judge.